Cardiome Pharma Corp (TSE:COM) (NASDAQ:CRME) insider David Cameron Peter Dean purchased 8,500 shares of Cardiome Pharma Corp stock in a transaction dated Wednesday, August 23rd. The stock was acquired at an average cost of C$2.70 per share, with a total value of C$22,950.00.

Cardiome Pharma Corp (TSE COM) traded up 3.66% during trading on Friday, reaching $2.83. The company had a trading volume of 56,853 shares. Cardiome Pharma Corp has a 52-week low of $2.63 and a 52-week high of $6.06. The company has a 50-day moving average of $5.11 and a 200-day moving average of $4.72. The firm’s market capitalization is $95.66 million.

WARNING: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/27/insider-buying-cardiome-pharma-corp-com-insider-acquires-c22950-00-in-stock.html.

Separately, HC Wainwright reissued a “buy” rating on shares of Cardiome Pharma Corp in a report on Wednesday, May 17th.

About Cardiome Pharma Corp

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients.

Receive News & Stock Ratings for Cardiome Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp and related stocks with our FREE daily email newsletter.